• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    12/10/25 8:30:53 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETHZ alert in real time by email
    false 0001690080 0001690080 2025-12-09 2025-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 9, 2025

     

    ETHZilla Corporation

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd, Suite 200
    Palm Beach, FL
      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 507-0669

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ETHZ   The NASDAQStock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    As previously disclosed in the Current Reports on Form 8-K filed by ETHZilla Corporation, formerly 180 Life Sciences Corp. (the “Company” , “we” and “us”), with the Securities and Exchange Commission (the “SEC”) on August 11, 2025, as amended by Amendment No. 1 thereto filed with the SEC on August 21, 2025 and September 22, 2025, as amended by Amendment No. 1 thereto filed with the SEC on September 25, 2025, on August 8, 2025, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with investment funds managed by an institutional investor (the “Investor”), under which the Company sold and issued to the Investor senior secured convertible notes (the “August 2025 Convertible Notes”) in an aggregate principal amount of $156,250,000, and on September 22, 2025, the Company entered into an Amendment and Waiver Agreement with the Investor (the “Amendment Agreement”), pursuant to which, among other things, the Company sold the Investor a new series of senior secured convertible (the “September 2025 Convertible Notes”, and together with the August 2025 Convertible Notes, the “Convertible Notes”) in the aggregate principal amount of $360 million. The Convertible Notes are secured by an aggregate of approximately $509,090,000 in cash (the “Cash Collateral”) and 11,374.893513 of Ether (ETH) having a value of approximately $37,789,000 (the “Specified ETH Amount”) as of December 9, 2025 (the “ETH Collateral”). Both the Cash Collateral and the ETH Collateral are held in restricted accounts in accordance with the agreements with the Investor.

     

    On December 9, 2025, the Company entered into a Note Mandatory Redemption Agreement (the “Redemption Agreement”) with the Investor, pursuant to which we agreed to repurchase and redeem the Convertible Notes for a purchase price equal to 117% of the aggregate outstanding principal amount of the Convertible Notes (approximately $516,148,000 as of December 9, 2025) plus accrued and unpaid interest, late charges (if any), and any other amounts (if any) owed by the Company to the Investor pursuant to the agreements governing the Convertible Notes as of the payoff date (the “Purchase Price”), with any portion of the Purchase Price that is not fully covered by the Cash Collateral (the “Remaining Payment Amount”), if any, being payable on or before December 24, 2025 (the “Partial Repayment Date”) and the balance of the Purchase Price being payable on or before December 30, 2025 (the “Mandatory Note Redemption Deadline”).

     

    The Company is permitted to use its balance sheet assets to repay the loan. In addition, under certain circumstances the Company is permitted to use the ETH control account to facilitate repayment, should it choose. If the Company has paid the full Remaining Payment Amount on or before the Mandatory Note Redemption Deadline, whether in cash or with proceeds of an ETH liquidation, the Cash Collateral account holder will be authorized to release any such amount of Cash Collateral necessary to pay the balance of the Purchase Price to the Investor. If the Company fails to pay the Purchase Price on or before the Mandatory Note Redemption Deadline, the Investor may terminate the Redemption Agreement upon written notice to the Company.

     

    The Redemption Agreement includes customary representations and warranties of the Company and the Investor, a general release of the Investor and the collateral agent, by the Company and its subsidiaries (effective on the actual payoff date), except as to obligations under the Release Agreement, and customary indemnification provisions (incorporated by reference from the Securities Purchase Agreement) binding the Company.

     

    Upon the full payment of the Purchase Price and the Investor’s legal fees, the Convertible Notes will be deemed cancelled.

     

    The foregoing description of the Redemption Agreement is not complete and is subject to, and qualified in its entirety by reference to the Redemption Agreement filed herewith as Exhibit 10.1, which is incorporated in this Item 1.01 by reference in its entirety.

     

    1

     

     

    Item 7.01 Regulation FD Disclosure.

     

    Press Release and Presentation

     

    On December 10, 2025, the Company filed a press release announcing the entry into the Redemption Agreement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

     

    The information in this Item 7.01 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1 is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    Number
      Description of Exhibit
    10.1*#   Note Mandatory Redemption Agreement dated December 9, 2025, by and among ETHZilla Corporation and the Investor party thereto
    99.1**   Press Release dated December 10, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    *Filed herewith.
    **Furnished herewith.
    #Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K. A copy of any omitted schedule or Exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that ETHZilla Corporation may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 10, 2025

     

      ETHZilla Corporation
       
      By: /s/ McAndrew Rudisill
        Name:  McAndrew Rudisill
        Title: Chief Executive Officer

     

    3

     

    Get the next $ETHZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETHZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ETHZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Suckling Andrew P

    4/A - ETHZilla Corp (0001690080) (Issuer)

    12/3/25 7:57:05 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Director New Jason Griffin

    4/A - ETHZilla Corp (0001690080) (Issuer)

    12/3/25 7:56:23 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Director Heter Crystal Jane

    4/A - ETHZilla Corp (0001690080) (Issuer)

    12/3/25 7:55:44 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Announces Plans to Effect Early Redemption of 2028 Convertible Notes to Streamline Capital Structure

    PALM BEACH, Fla., Dec. 10, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company") today announced that it intends to redeem in full its outstanding $516 million in aggregate principal amount of convertible notes due 2028 (the "Convertible Notes") on or by December 30, 2025, at a purchase price of 117% of the outstanding aggregate principal amount of the Convertible Notes, plus all accrued and unpaid interest and any other amounts due thereon. The Company intends to release the restricted cash on hand pledged as collateral to facilitate the redemp

    12/10/25 8:30:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla and Zippy Enter into Definitive Agreements with Plans to Tokenize Manufactured Home Loans On-Chain, ETHZilla Takes 15% Stake in Zippy

    Latest strategic investment further advances ETHZilla's real-world asset strategy, with plans to extend tokenization capabilities to manufactured housing finance PALM BEACH, Fla., Dec. 10, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bringing decentralized finance infrastructure to traditional finance, today announced the entry into several agreements with Zippy, Inc. ("Zippy"), a modern, institutionally ready digital lending platform with the goal of bringing manufactured home loans, one of America's most underserved credit markets, on-chain as tokenized real-world assets (RWAs). Under the terms of the agreements, ETHZilla will

    12/10/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Integrates Karus to Power AI-Modeled Auto Loan Tokenization

    Strategic transaction seeks to combine Karus's predictive credit analytics with ETHZilla's blockchain infrastructure to bring real-world credit investments on-chain PALM BEACH, Fla., Dec. 3, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bringing decentralized finance infrastructure to traditional finance, today announced the acquisition of a 20% fully-diluted interest in Karus, Inc. ("Karus"), a leading artificial intelligence (AI) platform for auto finance decisioning and portfolio analytics. Pursuant to the transaction, ETHZilla plans to integrate Karus's AI-driven underwriting into its blockchain infrastructure, enabling the to

    12/3/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    SEC Filings

    View All

    ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    12/10/25 4:30:27 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    12/10/25 8:30:53 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    12/10/25 8:01:40 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Leadership Updates

    Live Leadership Updates

    View All

    ETHZilla names John Kristoff as SVP, Corporate Communications and Investor Relations

    PALM BEACH, Fla., Oct. 16, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), a leading technology company connecting traditional finance with decentralized finance, today announced the appointment of John D. Kristoff as Senior Vice President, Corporate Communications and Investor Relations. He will report directly to Chairman and CEO McAndrew Rudisill. In this newly created role, Kristoff will lead ETHZilla's communications and investor relations strategies, shaping the company's narrative and deepening engagement with both the media and investors. He will also play a k

    10/16/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces Appointment of Jason New to Board of Directors

    PALM BEACH, Fla., Oct. 8, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), today announced that Jason New, Vice Chairman of Investment Banking at Lazard, has been appointed as a member of its Board of Directors, effective immediately. Mr. New brings more than two decades of experience in global credit, private equity, and alternative investments. He previously co-founded NovaWulf Management, a digital-asset investment and infrastructure platform, and served as Chief Executive Officer of Onex Credit Partners, a $25 billion alternative credi

    10/8/25 7:59:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Financials

    Live finance-specific insights

    View All

    ETHZilla Integrates Karus to Power AI-Modeled Auto Loan Tokenization

    Strategic transaction seeks to combine Karus's predictive credit analytics with ETHZilla's blockchain infrastructure to bring real-world credit investments on-chain PALM BEACH, Fla., Dec. 3, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bringing decentralized finance infrastructure to traditional finance, today announced the acquisition of a 20% fully-diluted interest in Karus, Inc. ("Karus"), a leading artificial intelligence (AI) platform for auto finance decisioning and portfolio analytics. Pursuant to the transaction, ETHZilla plans to integrate Karus's AI-driven underwriting into its blockchain infrastructure, enabling the to

    12/3/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Reports Third Quarter 2025 Financial Results

    Company generates $4.1 million in revenue in first six weeks operating as ETHZilla; Accelerates RWA tokenization initiatives PALM BEACH, Fla., Nov. 14, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company connecting traditional finance and decentralized finance (DeFi), today announced financial results for the third quarter ended September 30, 2025. Management Commentary "This quarter marked a transformative leap for ETHZilla, establishing us as a technology leader in DeFi and positioning us for real-world asset (RWA) toke

    11/14/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care